Back to search results

Genomic Testing and Targeted Therapies for Cancer

This study is looking at how well a "Therapeutic Intervention" (a type of drug treatment) works when it's chosen based on genetic testing of a person's cancer. It's for adults (18 years or older) who have cancer that has either not responded to their first treatment or for whom there are no other options for a cure. The main goal is to see how long people live without their cancer getting worse (Progression Free Survival) for up to two years after starting the targeted therapy. The study's current status is unclear, and it plans to enroll about 93 participants.

Study design
This is a single-arm study, meaning all participants receive the same intervention. It will involve about 93 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to measure Progression Free Survival for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03089554

Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

Recruiting
PHASE2Ages 18+InterventionalTreatment
Rachel Miller
~93 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:Therapeutic Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression Free Survival
Measured over 2 years

Conditions

Cancer

Explore related trials

Hematologic NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
Kentucky1

Study leadership

  • RACHEL MILLER, MD · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

RACHEL MILLER, MD
[email protected]
859-323-2196
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with clinically suspected or histologically confirmed solid or hematological malignancy who have undergone or will undergo genetic testing of their tumor
Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.
Patients must have either measurable or non-measurable disease.
Age ≥18 years.
Eastern Cooperative Oncology Group performance status ≤3.
Patients with brain metastasis must have had treatment of their brain metastasis completed at least 1 day prior to enrollment and be on stable dose of steroids or off steroids at the time of enrollment.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion

Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.
Pregnant women are excluded from this study.
HIV positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible.

What this trial measures

  • Progression Free Survival2 years

    Proportion of patients achieving a PFS ratio ≥1.3.